Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Replimune Group has raised $140.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2024.
Replimune Group's investors include Foresite Capital, Cormorant Asset Management, Redmile Group, Bain Capital Life Sciences, Hercules Capital.
Replimune Group is headquartered in Woburn, United States.
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Replimune Group is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Replimune Group — Funding & Investors." VCBacked, November 25, 2024, https://www.vcbacked.co/company/replimune-group. Accessed November 11, 2026.
VCBacked. (2024). Replimune Group — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/replimune-group
{{cite web |title=Replimune Group — Funding & Investors |url=https://www.vcbacked.co/company/replimune-group |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Replimune Group? Request a listing update